FindTrial
Sign In

Comparative study of Intradermal versus Intralesional Purified Protein Derivative (PPD) for treatment of common warts in children

To Compare the efficacy and safety of Intradermal versus Intralesional Purified Protein Derivative (PPD) for treatment of Common warts in children

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2019/07/020070
Enrollment
100
Registered
2019-07-08
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L088- Other specified local infections of the skin and subcutaneous tissue

Interventions

Intervention1: Injection purified protein derivative: Given as 10 tuberculin units per 0.1ml intradermal and Intralesional at 2,4,6,8 weeks interval and patient asked to return for follow up at 12week

Sponsors

Himachal Pradesh University
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Children of age 5 to 15 years clinically diagnosed with common warts

Exclusion criteria

Exclusion criteria: Patients with immune suppression from any disease or drug therapy

Design outcomes

Primary

MeasureTime frame
Not yet recruitingTimepoint: Not yet recruiting—

Secondary

MeasureTime frame
NATimepoint: NA—

Countries

India

Contacts

Public ContactDr Monika chandel

Department of dermatology Dr rpgmc tanda

drkaranindermehta@gmail.com9418457647

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026